Abstract: The present invention relates to methods and kits to assess an absorbed dose of ionizing radiation and/or the severity of tissue injury from radiation in a patient. The invention also relates to algorithms used to calculate an absorbed dose of radiation based on biomarker measurements of a plurality of biomarkers that are altered relative to a normal control in the event of radiation exposure.
Type:
Application
Filed:
August 29, 2019
Publication date:
January 9, 2020
Applicants:
MESO SCALE TECHNOLOGIES, LLC, THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
Inventors:
William F. Blakely, Eli N. Glezer, John Kenten, Sudeep Kumar, Anu Mathew, Natalia I. Ossetrova, George Sigal
Abstract: Methods for inducing an immune response against Human Immunodeficiency Virus (HIV) in HIV-infected subjects undergoing antiretroviral therapy (ART) are described. The methods include administering an adenovirus vector primer vaccine and a modified vaccinia virus (MVA) vector booster vaccine encoding mosaic HIV antigens.
Type:
Grant
Filed:
April 16, 2019
Date of Patent:
January 7, 2020
Assignees:
Janssen Vaccines & Prevention B.V., Beth Israel Deaconess Medical Center, Inc., THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC., The Government of The United States, as represented by The Secretary Of The Army
Inventors:
Frank Tomaka, Maria Grazia Pau, Johanna Schuitemaker, Dan Barouch, Jintanat Ananworanich, Merlin Robb, Nelson L. Michael, Jerome Kim
Abstract: A graft containing a scaffold that includes a matrix in which are positioned mesenchymal progenitor cells (MPCs) has the capacity to substantially improve wound healing, including wounds resulting from injury to nerve, bone and vascular tissue. MPCs can be harvested from debrided muscle tissue following orthopaedic trauma. The traumatized muscle-derived progenitor cells are a readily available autologous cell source that can be utilized to effect or improve wound healing in a variety of therapeutic settings and vehicles.
Type:
Grant
Filed:
February 12, 2014
Date of Patent:
December 17, 2019
Assignees:
THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC., THE UNITED STATES GOVERNMENT, AS REPRESENTED BY THE SECRETARY OF THE ARMY, U.S.A., THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
Inventors:
Wesley M. Jackson, Leon J. Nesti, Rocky S. Tuan
Abstract: Described herein are systems and methods for determining if a subject has an increased risk of having or developing pneumonia or symptoms associated with pneumonia. Also described are systems and methods for predicting a pneumonia outcome for a subject, systems and methods for generating a model for predicting a pneumonia outcome in a subject, systems and method for determining a subject's risk profile for pneumonia, method of determining that a subject has an increased risk of developing pneumonia, and methods of treating a subject determined to have an elevated risk of developing pneumonia, methods of detecting panels of biomarkers in a subject, and methods of assessing risk factors in a subject having an injury, as well as related devices and kits.
Type:
Application
Filed:
January 5, 2018
Publication date:
November 21, 2019
Applicant:
Henry M. Jackson Foundation for the Advancement of Military Medicine
Inventors:
Seth A. Schobel, Eric A. Elster, Beverly J. Gaucher
Abstract: Described herein are systems and methods for determining if a subject has an increased risk of having or developing bacteremia or symptoms associated with bacteremia. Also described are systems and methods for predicting a bacteremia outcome for a subject, systems and methods for generating a model for predicting a bacteremia outcome in a subject, systems and method for determining a subject's risk profile for bacteremia, method of determining that a subject has an increased risk of developing bacteremia, and methods of treating a subject determined to have an elevated risk of developing bacteremia, methods of detecting panels of biomarkers in a subject, and methods of assessing risk factors in a subject having an injury, as well as related devices and kits.
Type:
Application
Filed:
January 5, 2018
Publication date:
November 21, 2019
Applicant:
Henry M. Jackson Foundation for the Advancement of Military Medicine
Inventors:
Seth A. Schobel, Eric A. Elster, Beverly J. Gaucher
Abstract: This invention provides compositions in the form of skin substitutes comprising epithelial cells and mesenchymal cells, wherein the mesenchymal cells are not isolated from the occipital or nape region of the scalp, as well as methods for using the same.
Type:
Grant
Filed:
May 1, 2014
Date of Patent:
November 19, 2019
Assignee:
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Inventors:
Rajesh Thangapazham, Thomas N. Darling, Shaowei Li
Abstract: Described are methods of treating or reducing the toxic effects of exposure to a nerve agent, comprising administering to a subject in need thereof (i) an AMPA/GluR5(GluK1) kainate receptor antagonist (such as LY293558) and (ii) an NMD A receptor antagonist (such as an antimuscarinic compound, such as caramiphen), as well as methods of treating, reducing the risks of, or preventing a neurological condition such as epilepsy, seizures, post-traumatic stress disorder, status epilepticus, depression, or anxiety, comprising administering to a subject in need thereof (i) an AMPA/GluR5(GluK1) kainate receptor antagonist (such as LY293558) and (ii) an NMDA receptor antagonist (such as an antimuscarinic compound, such as caramiphen). The methods may further comprise administering a positive allosteric modulator of synaptic GABAA receptors, such as a benzodiazepine, such as midazolam, to the subject. The methods are suitable for use in children and adults. Related compositions and uses also are described.
Type:
Application
Filed:
June 9, 2017
Publication date:
October 24, 2019
Applicant:
THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
Abstract: The present disclosure is directed to an immunogenic composition including: at least one or at least two isolated polypeptides or immunogenic fragments thereof, and optionally a pharmaceutically acceptable carrier, wherein each polypeptide is expressed on a luminal surface of an intestine of a filarial worm, wherein each polypeptide is expressed at a level at least two-fold higher in the intestine in comparison to the level of expression of each polypeptide in a reproductive tract or a body wall of the filarial worm, wherein each isolated polypeptide has at least one transmembrane domain, and wherein each polypeptide is a non-mitochondrial polypeptide. Also provided herein is a method for preventing or treating a filarial disease.
Type:
Grant
Filed:
March 17, 2016
Date of Patent:
October 15, 2019
Assignees:
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The United States Government, as Represented by the Secretary of the Department of Health and Human Services
Inventors:
Edward E. Mitre, Christopher Morris, Sasisekhar Bennuru, Thomas Nutman
Abstract: The present invention relates to methods and kits to assess an absorbed dose of ionizing radiation and/or the severity of tissue injury from radiation in a patient. The invention also relates to algorithms used to calculate an absorbed dose of radiation based on biomarker measurements of a plurality of biomarkers that are altered relative to a normal control in the event of radiation exposure.
Type:
Grant
Filed:
September 15, 2015
Date of Patent:
October 8, 2019
Assignees:
Meso Scale Technologies, LLC, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Inventors:
William F Blakely, Eli N. Glezer, John Kenten, Sudeep Kumar, Anu Mathew, Natalia I. Ossetrova, George Sigal
Abstract: The present invention provides for methods of measuring levels of micro RNAs for the diagnosis, treatment and/or monitoring the progression of post-traumatic stress disorder (PTSD) or traumatic brain injury (TBI) in a subject having or suspected of having PTSD and/or TBI. The methods, in general comprise measuring levels of at least one of miR-142-5p, miR-19b, miR-1928, miR-223-3p, miR-322*, miR-324, miR-421-3p, miR-463* and miR-674* is a sample from a subject suffering from or suspected of having PTSD and/or TBI.
Type:
Grant
Filed:
April 21, 2015
Date of Patent:
August 6, 2019
Assignee:
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Inventors:
Radha K. Maheshwari, Nagaraja S. Balakathiresan, Manish Bhomia, Raghavendar Chandran
Abstract: The invention relates to methods of treating or preventing organophosphate poisoning in a subject in need thereof, comprising administering to the subject isoflurane, enflurane, halothane, sevoflurane, desflurane, xenon or argon in a therapeutically effective amount.
Type:
Application
Filed:
September 18, 2017
Publication date:
August 1, 2019
Applicant:
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Inventors:
Jishnu K.S. KRISHNAN, Aryan M. NAMBOODIRI, John R. MOFFETT, Arun PEETHAMBARAN, Narayanan PUTHILLATHU, Ranjini VENGILOTE
Abstract: Methods of detecting or diagnosing posttraumatic stress disorder (PTSD) in a human subject are disclosed. In addition, methods of monitoring the progression of PTSD in a human subject, methods of treating a patient with PTSD, kits for diagnosing PTSD in a human subject suspected of having PTSD, and methods of detecting a microRA (miRNA) or plurality of miRNAs in a biological sample from a human subject are also disclosed.
Type:
Grant
Filed:
September 25, 2015
Date of Patent:
July 23, 2019
Assignee:
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Abstract: The present invention generally relates to the production of antigen-specific T regulatory cells (Tregs). Such cells can be used in therapy to minimize undesirable immune responses such as those observed in autoimmunity and hemophilia and other diseases as well as in the response to protein therapy for genetic diseases. Methods for producing antigen specific Tregs and conditions for preferential expansion of functionally stable, specific Tregs are also provided.
Type:
Application
Filed:
September 6, 2018
Publication date:
July 4, 2019
Applicant:
THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
Abstract: The present system is directed in several embodiments to a method of administration of a therapeutic composition for protection of the brain of a subject at risk of injury leading to traumatic brain injury (TBI) and/or treatment of injury to the brain resulting from TBI. The method includes administering one or more therapeutic compositions comprising an effective amount of insulin directly to the subject patient's CNS, with no to minimal systemic exposure. Preferably, this method comprises administration of an effective amount of insulin to the upper third of a patient's nasal cavity, thereby bypassing the patient's blood-brain barrier and delivering the therapeutic composition directly to the patient's central nervous system.
Type:
Grant
Filed:
April 6, 2015
Date of Patent:
June 11, 2019
Assignees:
HealthPartners Research & Education, The Henry M. Jackson Foundation for Advancement of Military Medicine, Inc.
Inventors:
William H. Frey, II, Leah Ranae Bresin Hanson, Kimberly Byrnes, Fiona Brabazon
Abstract: Methods for inducing an immune response against Human Immunodeficiency Virus (HIV) in HIV-infected subjects undergoing antiretroviral therapy (ART) are described. The methods include administering an adenovirus vector primer vaccine and a modified vaccinia virus (MVA) vector booster vaccine encoding mosaic HIV antigens.
Type:
Grant
Filed:
September 1, 2017
Date of Patent:
June 4, 2019
Assignees:
Janssen Vaccines & Prevention B.V., The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Beth Israel Deaconess Medical Center, Inc., The United States of America, as represented by The Secretary Of The Army
Inventors:
Frank Tomaka, Maria Grazia Pau, Johanna Schuitemaker, Dan Barouch, Jintanat Ananworanich, Merlin Robb, Nelson L. Michael, Jerome Kim
Abstract: The disclosure describes alterations in ERG gene expression. ERG isoforms and promoter sequence of the ERG gene that are involved in, or associated with, prostate cancer are provided. The disclosure further provides therapeutic compositions and methods of detecting, diagnosing, prognosing, and treating prostate cancer, including biomarkers for detecting the expression of two or more of the following genes: PSA/KLK3, PMEPA1, NKX3.1, ODC1, AMD1, and ERG.
Type:
Grant
Filed:
August 22, 2013
Date of Patent:
May 14, 2019
Assignee:
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Inventors:
Shiv Srivastava, Albert Dobi, Taduru Sreenath, Gyorgy Petrovics, Chen Sun
Abstract: The invention provides a method for the creation of peptide antigens comprising epitopes with at least a first modification comprising a shortened or lengthened amino acid side chain. By extension or shortening of the side chain with CH3/CH2 groups, for example, made by computer assisted modeling of the tumor antigen (peptide) bound in the MHC-I-groove, immunogenicity can be improved with minimal modification of adjacent tertiary structure, thereby avoiding cross-reactivity. Provided by the invention are methods of creating such antigens, as well as methods for therapeutic or prophylactic treatment of various conditions comprising administration of the antigens.
Type:
Grant
Filed:
July 29, 2014
Date of Patent:
March 26, 2019
Assignees:
Board of Regents, The University of Texas Systems, Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Inventors:
Constantin G. Ioannides, Martin L. Campbell, Catherine A. O'Brian, George E. Peoples
Abstract: Selective azophenol inhibitors of a wild type or an altered ERG protein expression are described, where the inhibitors represent a compound of Formula (I) or Formula (II) wherein X, X1, X2, X3, X4 and X5, R1 through R4 and R9 are as described.
Type:
Grant
Filed:
September 9, 2016
Date of Patent:
March 26, 2019
Assignee:
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Inventors:
Albert L. Dobi, Clifton L. Dalgard, Shiv K. Srivastava